ArticleEpilepsia open2025
Efficacy and tolerability of perampanel as add-on therapy in Dravet syndrome: A prospective real-world study.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MonoPER study: Effectiveness and tolerability of PERampanel in monotherapy in real-world after 12 months of treatment.Epilepsia open · 2025Observational
- Efficacy and tolerability of perampanel as add-on therapy in Dravet syndrome: A prospective real-world study.Epilepsia open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo investigate the efficacy and tolerability of perampanel (PER) on Dravet syndrome in China by a prospective real-world study.
methodsWe prospectively enrolled children with Dravet syndrome from the neurology clinic of Shenzhen Children's Hospital from September 2020 to October 2021. The average monthly seizure frequency within 2 months before enrollment was recorded as the baseline. PER was administered after enrollment. The response rate (the rate of seizure reduction ≥50% compared to the baseline) was regarded as the major index. The adverse events and retention rates were regarded as the minor index. All indexes were calculated after 3 and 6 months' follow-up, respectively. The outcome-predictive value of various clinical factors was analyzed.
resultsA total of 21 children were enrolled, including 15 boys and 6 girls, with a median age of 4 years and 8 months (1 year and 3 months to 15 years and 6 months). Averagely, 2.57 ASMs had been administrated and failed to control seizures before enrollment. The response rates were 52.4% (11/21) and 47.6% (10/21) after 3 and 6 months of PER administration, respectively. Adverse events were observed in 8 patients (38.1%), including irritability (3/8, 37.5%), fatigue (3/8, 37.5%), unstable walking (2/8, 25%), somnolence (2/8, 25%), and sluggish response (2/8, 25%); most of them were mild and temporary. The retention rate was 90.5% (19/21) at 6 months' follow-up. Two patients discontinued PER due to failure of seizure control, and no patients discontinued due to adverse events. SIGNIFICANCE: This study provides a comprehensive analysis of PER's effectiveness and tolerability in treating DS, highlighting its importance as an additional treatment option. It broadens the range of anti-seizure medications (ASMs) that may be effective for patients with DS. PLAIN LANGUAGE SUMMARY: In the neurology clinic of Shenzhen Children's Hospital, 21 children with Dravet syndrome were administered perampanel. Perampanel, as a novel anti-seizure medication approved for focal and generalized epilepsies as add-on therapy, showed sufficient efficacy and a satisfactory safety and tolerability profile in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.